Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer
|
|
- Sydney Conley
- 6 years ago
- Views:
Transcription
1 european urology supplements 5 (2006) available at journal homepage: Review Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer Dr. Donald Lamm is President of BCG Oncology in Phoenix, Arizona and Clinical Professor at the University of Arizona. He has had a lifelong interest in urologic oncology and clinical trials and has a particular interest in immunotherapy and chemoprevention. He is former professor of urology at the Mayo Clinic, Scottsdale, Arizona, and professor and chief of urology at West Virginia University and the University of Texas, San Antonio. Donald Lamm * BCG Oncology, North 40th Street, Suite E, Phoenix, AZ, United States Article info Published online ahead of print on June 5, 2006 Keywords: BCG immunotherapy Maintenance schedule Progression Recurrence Please visit to read and answer the EU-ACME questions on-line. The EU-ACME credits will then be attributed automatically. Abstract Bacillus Calmette-Guérin (BCG) immunotherapy has been demonstrated in randomised clinical trials and meta-analyses to provide superior protection from tumour recurrence and, unlike chemotherapy, even reduce disease progression. Although the optimal maintenance schedule has not been defined by controlled comparison, review of controlled studies suggests that Dr. Lamm s 3-wk schedule with maintenance at 3, 6, 12, 18, 24, 30, and 36 mo may be best, but dose reduction and delay or suspension of treatments is frequently needed to reduce side-effects. Randomised comparison of this regimen using full-strength Connaught BCG versus one-third strength suggests the former is superior, but in some populations dose reduction may be superior. Moreover, long-term (15-yr) follow-up of BCG-treated patients demonstrates the need for continued protection from recurrence and progression. These considerations, plus the marginal improvement demonstrated with systemic BCG immunisation and the reduction in side-effects with dose reduction have led Dr. Lamm to use the following protocol. Induction consists of full-strength BCG given weekly for 6 wk with concomitant percutaneous administration. The dose is reduced to one third at the first sign of significant side-effects. Maintenance BCG in high-risk (G3, T1, or CIS) patients is given using one-third dose BCG at 3, 6, 12, 18, 24, 36, 48, 60, and 72 mo, and then every other year to the 12th year, with dose reductions to 1/10th, 1/30th, 1/100th as needed to prevent increasing side-effects. # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Tel ; Fax: address: dlamm@bcgoncology.com /$ see front matter # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eursup
2 european urology supplements 5 (2006) Introduction Bacillus Calmette-Guérin (BCG) immunotherapy has been demonstrated in randomised clinical trials and meta-analyses to provide superior protection from tumour recurrence and, unlike chemotherapy, even reduce disease progression. Optimal BCG therapy, however, is an individual affair. Optimal treatment varies according to multiple host and tumour factors. Host factors for BCG include age, general immune status, previous exposure to BCG, and BCG response gene. Tumour factors include location, stage, grade, antigenicity, and doubling time, among others. Risk groups also improve treatment selection. Low-risk groups include G1, Ta solitary tumours with no recurrence at 3 mo. Intermediate-risk groups include multiple or recurrent G1Ta and G2Ta. High-risk groups are any G3, carcinoma in situ (CIS), lamina propria invasion (T1) tumours, or 3-mo recurrence. Low-grade tumors are relatively resistant to BCG immunotherapy. In a study of intravesical BCG and epirubicin comparing the prophylaxis of recurrent or multiple superficial bladder tumours, a significant advantage for BCG was only observed in T1 and G3 transitional cell carcinoma (TCC) [1]. 2. Diet and lifestyle as an adjunct to BCG therapy Diet, lifestyle, and environmental factors also play a significant role in reducing risk. Diets low in vitamin A and serum carotene and high in fat increase the risk of bladder cancer. Soy, garlic, selenium, nonsteroidal anti-inflammatory drugs, and green tea may reduce the risk. Furthermore, vitamins such as A, B 6, C, E, and possibly folic acid and D, may be protective. Megavitamin supplements (Oncovite), with higher than recommended dietary allowance of vitamins A, B 6, C, and E, have been shown to reduce overall recurrence of bladder cancer from 80% to 40% ( p = ) in patients receiving BCG therapy for bladder carcinoma (Fig. 1). In Ta and T1 TCC, recurrence was reduced by 42%, and recurrence in low-grade (G1, G2) TCC was reduced by 53%. Oncovite was also associated with a statistically significant increase in long-term natural killer (NK) cell activity in patients treated with BCG [2]. The benefit of high-dose vitamins is currently being evaluated again in patients receiving optimal BCG maintenance therapy with or without interferon alfa. 3. Chemotherapy Intravesical therapy (with chemotherapeutic agents or BCG) is most often used in patients with multiple tumours or recurrent tumours or as a prophylactic measure in high-risk patients after transurethral resection (TUR). A meta-analysis of seven randomised trials that included close to 1500 patients evaluated tumour recurrence in Ta, T1 TCC after a single postoperative chemotherapy and showed that instillation within 6 h is clearly effective [3]. Comparison studies show that single immediate chemotherapy treatment after TUR is better than delayed, extended treatment. One instillation, however, may be insufficient with multiple tumours [3]. 4. BCG versus chemotherapy Many studies in superficial TCC of the bladder found that BCG was associated with significantly fewer recurrences than mitomycin C. In our Southwest Oncology Group (SWOG) study, although there was no significant difference seen in disease progression, recurrence with grade 3 superficial disease was significantly lower in patients being treated with BCG. Overall reduction in tumour recurrence is illustrated in Fig. 2. A meta-analysis of randomised trials showed that intravesical BCG is superior to mitomycin C in reducing tumour recurrence in high-risk TCC [5]. Fig. 1 Kaplan Meier estimate of 5-yr tumour-free rate in patients receiving vitamin supplement and BCG therapy for bladder carcinoma [2]. 5. CIS In a meta-analysis of nine randomised trials including 700 patients with CIS [6], BCG therapy
3 656 european urology supplements 5 (2006) Evidence indicates that doses of BCG as low as 1 mg (1/50th the standard dose) are effective in supporting an immune response 5 yr after starting treatment [9]. Comparison studies using dose reduction, however, have not been done. Initial immune stimulation peaks at 6 wk, but with subsequent courses it usually peaks at 3 wk, and the stimulation wanes with time. Furthermore, Th1 immune component host and antigenic tumour are needed for effectiveness. Fig. 2 BCG versus mitomycin C (Southwest Oncology Group 8795) [4]. showed 68% complete response compared to 52% complete response in chemotherapy-treated patients ( p = ). With a 3.6-yr mean followup, 47% of BCG-treated patients showed no evidence of disease compared to 26% of chemotherapy patients. Patients treated with BCG also showed 26% reduction in disease progression. This shows that BCG reduces the risk of short- and long-term treatment failure compared with chemotherapy, and BCG should be the agent of choice in the treatment of CIS. 6. BCG versus TUR alone Meta-analysis of six trials with 585 patients of BCG versus TUR alone showed that BCG provides significantly better prophylaxis of tumour recurrence in Ta, T1 TCC. In terms of first recurrence, a 56% reduction in the hazard was attributable to BCG, whereas the odds ratio for recurring at 12 mo significantly favoured BCG therapy [7]. 7. Principles of BCG immunotherapy Optimal BCG therapy is based on several goals and principles. The goal of BCG therapy is to minimise the tumour burden by juxtaposing BCG and tumour cells. Intravesical administration of BCG generally provides good juxtaposition for TCC within the bladder. The urologist should use sufficient but not excess BCG. Excess BCG, such as repeated 6-wk courses, suppresses the immune response. Individual responses vary, but using too little or too much BCG reduces its effect. The dose-response curve is bell-shaped (as illustrated by murine models) [8]. 8. Low-dose versus high-dose BCG Intravesical BCG is effective in the prophylaxis of papillary tumour recurrences, in the therapy of CIS, and in delaying progression to muscle invasion. A low-dose regimen (BCG, 75 mg) achieved clinically significant response rates with a decrease in sideeffects compared with standard-dose BCG (150 mg). Patients having a low-dose BCG regimen showed significantly better response rates ( p = ) and a significant decrease in most of the common sideeffects (cystitis, fever, and haematuria; p < 0.05). Although no differences in progression rates were observed, a higher proportion of T1 patients receiving the low-dose BGC regimen were free of tumours [10]. Low-dose BCG after one-cycle BCG failure provides 60% durable complete response. Chemotherapy for BCG failures, however, provides poor response rates (19% for mitomycin C) [11]. 9. Maintenance 9.1. Effect on recurrence A comparison of BCG and doxorubicin in patients with bladder TCC also showed that BCG provided long-term protection against recurrence (Fig. 3) [12]. Fig. 3 BCG versus doxorubicin: treatment failure free [12].
4 european urology supplements 5 (2006) Fig. 4 BCG maintenance [15]. Moreover, an evaluation of 3-wk BCG maintenance found no significant increase in toxicity during further maintenance [13] Effect on progression A 15-yr follow-up of Ta and T1 patients showed that without BCG maintenance 5% of TaG1 patients progressed, 39% of TaG3 patients progressed and 26% died, and 56% T1G3 patients progressed and 38% died. These results show that patients with highgrade Ta tumours have a lifelong risk of disease stage progression similar to those with T1 tumors [14]. Although BCG immunotherapy has been widely accepted as the optimal treatment for CIS and highgrade superficial TCC, controversy remains regarding the role of maintenance therapy, and its longterm effect on recurrence and progression. Compared to standard induction therapy, maintenance BCG immunotherapy has been beneficial in patients with CIS and select patients with Ta, T1 bladder cancer (Fig. 4). Median recurrence-free survival in patients with maintenance was twice as long compared to no maintenance ( p < ) [15]. A meta-analysis of 24 randomised trials showed that BCG significantly reduced the risk of progression after TUR in patients with intermediate- and high-risk papillary tumours and those with CIS who receive maintenance treatment. BCG, however, was only effective in trials with maintenance, where it reduced the risk of progression by 37% ( p = ). In terms of survival, the reduction in the odds of death of 11% overall and 19% in bladder cancer were not statistically significant, as might be expected with 2.5-yr mean follow up [16]. 10. Percutaneous BCG Although studies have failed to demonstrate benefit for percutaneous BCG, complete response in CIS patients increased from 49% to 77% with purified protein derivative (PPD) conversion ( p < 0.001) [15]. PPD is clearly not a requisite for response to BCG, but statistically significant correlations have been reported. Although percutaneous BCG and PPD skin testing add virtually nothing to the morbidity or cost of treatment, immune status is clearly related to the course of cancer and PPD is a measure of cellular immunity. Although data are controversial, percutaneous BCG for PPD-negative patients may be beneficial and is worthy of study. 11. Predicting BCG response Molecular markers Overexpression of p53, tumor suppression gene, does not predict response to BCG [17,18]. Proliferation rate, however, assessed by Ki-67 protein using MBI-1 antibody, could be a useful predictive marker of outcome in T1G3 bladder carcinoma. Patients
5 658 european urology supplements 5 (2006) with <20% expression were associated with a positive response to BCG instillations [19] Urinary leukocytes A study of urinary leukocyte count on the third day after BCG treatment in patients treated with 3-wk maintenance BCG showed that a white blood cell count of 165,000/ml was associated with significant reduction in tumour recurrence ( p = ) and increase in side-effects ( p = ) [20]. 12. Proposed optimal BCG maintenance schedule Although the optimal maintenance schedule has not been defined by controlled comparison, review of controlled studies suggests that a 3-wk schedule with maintenance at 3, 6, 12, 18, 24, 30, and 36 mo may be best, but dose reduction and delay or suspension of treatments is frequently needed to reduce side-effects. Randomised comparison of this regimen using full-strength Connaught BCG versus one-third strength suggests the former is superior, but in some populations dose reduction may be superior. Moreover, long-term (15-yr) follow up of BCGtreated patients demonstrates the need for continued protection from recurrence and progression. These considerations plus the marginal improvement demonstrated with systemic BCG immunisation and the reduction in side-effects with dose reduction have led me to use the following protocol. Induction consists of full-strength BCG given weekly for 6 wk with concomitant percutaneous administration. Percutaneous administration is given by the Tine technique. The inner upper thigh is cleansed with alcohol, wet with 2 drops of the BCG suspension to be instilled in the bladder, and then punctured 4 times with a 28-gauge needle. Percutaneous BCG is discontinued when significant or bothersome inflammation occurs. The dose of intravesical BCG is reduced to one third at the first sign of significant side-effects. Maintenance BCG in high risk (G3, T1, or CIS) patients is given using onethird dose BCG at 3, 6, 12, 18, 24, 36, 48, 60, and 72 mo, and then every other year to the 12th year, with dose reductions to 1/10th, 1/30th, 1/100th as needed to prevent increasing side-effects. 13. Conclusions Maintenance with BCG immunotherapy is the current standard treatment for intermediate- and high-risk TCC. Low-risk patients benefit from immediate perioperative chemotherapy. Diet, carcinogen reduction, and Oncovite supplements can also have a significant effect on treatment. In terms of managing BCG side-effects, dose reduction of BCG is a less toxic and less expensive alternative to isoniazid, but isoniazid and fluoroquinolone antibiotics are important in the treatment of infectious complications of BCG. The proposed BCG maintenance schedule is what the author now uses, but it has yet to be proven by randomised clinical trials. The schedule is based on the goals of reducing side-effects and improving ability to tolerate the maintenance treatment. References [1] Melekos MD, Zarakovitis IE, Fokaefs ED, et al. Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Oncology 1996;53: [2] Lamm DL, Riggs DR, Shriver JS, vangilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994;151:21 6. [3] Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171: quiz [4] Lamm DL, Blumenstein BA, Crawford ED, et al. Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a Southwest Oncology Group study. Urol Oncol 1995;1: [5] Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93: [6] Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174: [7] Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88: [8] Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol 1982;128: [9] Rivera P, Orio M, Hinostroza J, et al. Our experience with 1 mg BCG vaccine instillation in T1 stage cancer of the bladder. Actas Urol Esp 1999;23:
6 european urology supplements 5 (2006) [10] Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995;27: [11] Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161: [12] Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitionalcell carcinoma of the bladder. N Engl J Med 1991;325: [13] van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44: [14] Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60 1. [15] Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163: [16] Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168: [17] Lacombe L, Dalbagni G, Zhang ZF, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol 1996;14: [18] Lebret T, Becette V, Barbagelatta M, et al. Correlation between p53 over expression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998;159: [19] Lebret T, Becette V, Herve JM, et al. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000;37: [20] Saint F, Irani J, Salomon L, Legrand P, Abbou CC, Chopin D. Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors. Prog Urol 2001;11:
SUPERFICIAL BLADDER CANCER MANAGEMENT
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence
More informationEfficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
S86 Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer Donald L. Lamm Department of Urology, West Virginia University, Morgantown In the United States, bladder cancer
More informationThe Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More information/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/05/1741-0086/0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000162059.64886.1c BACILLUS CALMETTE-GUERIN
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationTHE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER
THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean
More informationCAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS
ADULT UROLOGY CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS RUI FA HAN AND JIAN GANG PAN ABSTRACT Objectives.
More informationMaintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive
Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk
More informationKyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang
www.kjurology.org DOI:.4/kju..5..65 Urological Oncology The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after
More informationBeware the BCG Failures: A Review of One Institution's Results
European Urology European Urology 42 (2002) 542±546 Beware the BCG Failures: A Review of One Institution's Results C. Richard W. Lockyer a,*, James E.C. Sedgwick b, David A. Gillatt a a Bristol Urological
More informationEUROPEAN UROLOGY 56 (2009)
EUROPEAN UROLOGY 56 (2009) 247 256 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Guido Dalbagni on pp. 257 258 of this issue
More informationProtocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008
Protocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008 {niftybox width=180px,float=right,textalign=left} update on the protocol: from Dr. Lamm's site: It is also true
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationbetter time to first recurrence compared to no adjuvant treatment. 1 3 Previous large randomized clinical trials performed
0022-5347/00/1634-1124/0 THE JOURNAL OF UROLOGY Vol. 163, 1124 1129, April 2000 Copyright 2000 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer
More informationIntravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationPatient Risk Profiles: Prognostic Factors of Recurrence and Progression
european urology supplements 5 (2006) 648 653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Patient Risk Profiles: Prognostic Factors of Recurrence and Progression
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationThe Role of Bacillus Calmette-Guérin in the Treatment of Non Muscle-Invasive Bladder Cancer
EUROPEAN UROLOGY 57 (2010) 410 429 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Bladder Cancer The Role of Bacillus Calmette-Guérin in the Treatment
More informationINTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 26 (3): 242-249, May - June, 2000 INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL
More informationMaintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer
710 Maintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer How Much Is Enough? Marc Decobert, PhD Helène LaRue, PhD François Harel, MSc François Meyer, MD Yves Fradet, MD Louis
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationONCOLOGY LETTERS 11: , 2016
ONCOLOGY LETTERS 11: 2751-2756, 2016 Comparison of intravesical bacillus Calmette Guerin and mitomycin C administration for non muscle invasive bladder cancer: A meta analysis and systematic review SHANG
More informationEarly Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non Muscle-Invasive Bladder Cancer
european urology supplements 8 (2009) 458 463 available at www.sciencedirect.com journal homepage: www.europeanurology.com Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned
More informationManagement of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS
Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of
More informationMixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome
DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
More informationSymptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography
Original Article ISSN 2465-8243(Print) / ISSN: 2465-8510(Online) https://doi.org/10.14777/uti.2017.12.1.42 Urogenit Tract Infect 2017;12(1):42-48 http://crossmark.crossref.org/dialog/?doi=10.14777/uti.2017.12.1.&domain=pdf&date_stamp=2017-04-25
More informationObjectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables.
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international
More informationEffectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up
Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 2, June: 121-126, 2007 in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up SAMIR EL-GHOBASHY, M.D.; TAREK R. EL-LEITHY,
More informationCritical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC
Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No
More informationCase by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1
Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1 Case Study 1 A 22-year-old man with a history of gross total painless hematuria: two times in two months, both after
More informationContents of Online Supporting Information. etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone
Contents of Online Supporting Information etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone etable 2. Study characteristics of head to head trials of intravesical therapy
More informationClinical Practice Recommendations for the Management of Non Muscle Invasive Bladder Cancer
european urology supplements 7 (2008) 651 666 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Practice Recommendations for the Management of Non Muscle Invasive Bladder
More informationIntravesical Gemcitabine: State of the Art
european urology supplements 6 (2007) 809 815 available at www.sciencedirect.com journal homepage: www.europeanurology.com Intravesical Gemcitabine: State of the Art Paolo Gontero *, Alessandro Tizzani
More informationManagement of Difficult Cases of Non-Muscle Invasive Bladder Cancer
Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer 1 Bladder Cancer Recurrence is common Progression is uncommon Progression is more important than recurrence There are indicators of recurrence
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationT1HG Bladder Cancer What is the Best Therapy?
T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationEuropean Urology 46 (2004) 65 72
European Urology European Urology 46 (2004) 65 72 Preliminary European Results of Local Microwave Hyperthermia and ChemotherapyTreatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationIntravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure
Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.
More informationPrognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy
European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten
More informationIAUN Conference Dublin, January Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist
IAUN Conference Dublin, January 2014 Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist Theoretical component Observation Supervised practice Assessment
More informationTheralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated
Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated First Four Patients Treated with Company s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary
More informationComparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer
EUROPEAN UROLOGY 63 (2013) 145 154 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by J. Alfred Witjes on pp. 155 157 of this
More informationA rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases
MOLECULAR AND CLINICAL ONCOLOGY 8: 785-790, 2018 A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MASAKAZU AKITAKE 1,
More informationPhase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer
Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer K. Hendricksen,* E. B. Cornel, T. M. de Reijke, H. C. Arentsen, S. Chawla and J. A. Witjes
More informationMICHAEL A. O DONNELL,* JANICE KROHN AND WILLIAM C. DEWOLF
0022-5347/01/1664-1300/0 THE JOURNAL OF UROLOGY Vol. 166, 1300 1305, October 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-
More informationPharmacologyonline 3: (2006)
INTRAVESICAL MISTLETOE EXTRACT FOR ADJUVANT TREATMENT OF SUPERFICIAL URINARY BLADDER CANCER P. Bühler 1, C. Leiber 1, M. Lucht 2, P. Wolf 1, U. Wetterauer 1, U. Elsässer-Beile 1 1 Department of Urology,
More information2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections
european urology supplements 8 (2009) 453 457 available at www.sciencedirect.com journal homepage: www.europeanurology.com 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms:
More informationThe value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice
48 Original Paper UROLOGICAL ONCOLOGY The value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice Rafał Walczak, Krzysztof Bar 2, Janusz Walczak Department
More informationEUROPEAN UROLOGY 59 (2011)
available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin
More informationimedpub Journals
Research Article imedpub Journals www.imedpub.com Journal of Clinical Medicine and Therapeutics Preventive Treatment with Diclofenac Suppositories May Improve BCG Induced Cystitis Symptoms without Affecting
More informationBacillus Calmette Guérin and Bladder Cancer
Review Article Bacillus Calmette Guérin and Bladder Cancer Azad H.A. Razack, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Bladder cancer is the second most
More informationIn 1999, bladder cancer was newly diagnosed in
REVIEW INTRAVESICAL THERAPY FOR BLADDER CANCER ASHISH M. KAMAT AND DONALD L. LAMM In 1999, bladder cancer was newly diagnosed in about 54,200 patients, and 12,100 patients died of this disease in the United
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More information14th Meeting of the EAU Section of Oncological Urology (ESOU)
Is Bacillus Calmette-Guerin (BCG) still the best adjuvant treatment after Trans Urethral Resection (TUR) for Ta-T1 high grade (G3) bladder cancer M. Brausi, Modena (IT) Introduction Bacillus Calmette-Guerin
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationResearch Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C
Bladder Cancer 1 (2015) 143 150 DOI 10.3233/BLC-150020 IOS Press Research Report 143 Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative
More informationManagement of BCG Failures in Superficial Bladder Cancer: A Review
european urology 49 (2006) 790 797 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer Management of BCG Failures in Superficial Bladder Cancer: A Review
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intravesical microwave hyperthermia with intravesical chemotherapy for superficial
More informationICUD-EAU International Consultation on Bladder Cancer 2012: Non Muscle-Invasive Urothelial Carcinoma of the Bladder
EUROPEN UROLOGY 63 (2013) 36 44 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer ICUD-EU International Consultation on Bladder Cancer 2012: Non Muscle-Invasive
More informationIntravesical Therapy for Urothelial Carcinoma of the Urinary Bladder: A Critical Review
Review Article Intravesical Therapy for Urothelial Bladder Carcinoma International Braz J Urol Vol. 35 (6): 640-651, November - December, 2009 doi: 10.1590/S1677-55382009000600002 Intravesical Therapy
More informationNaim B Farah 1*, Rami Ghanem 2 and Mahmoud Amr 3
Farah et al. BMC Urology 2014, 14:11 RESEARCH ARTICLE Open Access Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in
More informationRadiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer
Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationManagement options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationCUA guidelines on the management of non-muscle invasive bladder cancer
Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney
More informationCUA guidelines on the management of non-muscle invasive bladder cancer
Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney
More informationClinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy
european urology 52 (2007) 752 759 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Clinical Utility of Fluorescent in situ Hybridization for the Surveillance
More informationGenerated by Foxit PDF Creator Foxit Software For evaluation only.
Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (3) No. (٣) 28 27 2 28 2 T3 T4 T2 T1 Ta TUR G3 G2 G1 * ٩ 27 2 Tishreen University Journal for Research and
More informationSequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
Bladder Cancer 1 (2015) 65 72 DOI 10.3233/BLC-150008 IOS Press Research Report 65 Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Ryan
More informationClinical Trials: Non-Muscle Invasive Bladder Cancer. Tuesday, May 17th, Part II
Clinical Trials: Non-Muscle Invasive Bladder Cancer Tuesday, May 17th, 2016 Part II Presented by Yair Lotan, MD is holder of the Helen J. and Robert S. Strauss Professorship in Urology and Chief of Urologic
More informationEuropean Urology 46 (2004)
European Urology European Urology 46 (2004) 339 343 Phase II Study to Investigate the Ablative Efficacy of Intravesical Administration of Gemcitabine in Intermediate-Risk Superficial Bladder Cancer (SBC)
More informationReview Article. Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
Review Article Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer Ashish M. Kamat,*, J. Alfred Witjes, Maurizio Brausi, Mark Soloway,jj Donald Lamm, Raj Persad, Roger
More informationPredicting Response to Intravesical Immunotherapy (BCG) in NMIBC
Predicting Response to Intravesical Immunotherapy (BCG) in NMIBC Ashish M. Kamat, MD, MBBS, FACS Professor of Urologic Oncology Wayne B. Duddlesten Professor of Cancer Research President, International
More informationMark Kowalski, Jacinthe Guindon, Louise Brazas, Celine Moore, Joycelyn Entwistle, Jeannick Cizeau, Michael A. S. Jewett* and Glen C.
A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin Mark Kowalski, Jacinthe Guindon,
More informationContemporary management of high-grade T1 bladder cancer Arnulf Stenzl
Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Dep. of Urology, Eberhard-Karls University, Tuebingen, Germany Treatment options in HG T1 BCa TUR-BT Primary and second resection (T0-status)
More informationUpdate on bladder cancer diagnosis and management
7 Update on bladder cancer diagnosis and management RICHARD T. BRYAN Although the basis of the diagnosis and management of urothelial bladder cancer has remained unchanged for two decades or more, there
More informationNeoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,
More informationMANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS
MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS This symposium took place on 12 th March 2016 as part of the European Association of Urology Congress 2016 in Munich, Germany
More informationPanel: A Case-based Approach to the Management of Bladder Cancer
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
More informationBJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy
2008 The Authors; Journal compilation 2008 BJU International Mini-review Article INVASIVE T1 BLADDER CANCER: INDICATIONS AND RATIONALE FOR RADICAL CYSTECTOMY STEIN and PENSON BJUI BJU INTERNATIONAL Invasive
More informationRole of Re-Resection in Non Muscle-Invasive Bladder Cancer
Review Special Issue: Bladder Cancer TheScientificWorldJOURNAL (2011) 11, 283 288 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2011.29 Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Harry W.
More informationBCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients
BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients Michael S. Cookson, MD, Professor and Chair Department of Urology University of Oklahoma Non-muscle Invasive Bladder Cancer Bladder
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of electrically-stimulated intravesical chemotherapy for superficial bladder
More informationResults. Objectives. Patients and methods. Conclusions
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/grade 3 bladder cancer treated with bacille Calmette Guerin Paolo Gontero 1, Richard
More informationTHE SIDE EFFECTS OF THE ADJUVANT INSTILLATIONAL TREATMENT WITH BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 1-2011 THE SIDE EFFECTS OF THE ADJUVANT INSTILLATIONAL TREATMENT WITH BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER
More information